Header Logo

Connection

Jacob Rotmensch to Antimetabolites, Antineoplastic

Back to Details
This is a "connection" page, showing publications Jacob Rotmensch has written about Antimetabolites, Antineoplastic.
Jacob Rotmensch
Connection Strength
0.087
Antimetabolites, Antineoplastic
  1. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2011 Apr; 121(1):118-21.
    View in: PubMed
    Score: 0.087
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.